Q2 2022 Verona Pharma PLC Earnings Call Transcript
Welcome to Verona Pharma's conference call. (Operator Instructions) Earlier this morning, Verona Pharma issued a press release announcing top line results from its Phase III ENHANCE-2 trial, evaluating nebulized ensifentrine for the maintenance treatment of COPD. The company also issued a press release announcing its financial results for the 3 months ended June 30, 2022. Copies of both press releases can be found on the Investor Relations tab on the corporate website, www.veronapharma.com.
Before we begin, I'd like to remind you that during today's call, statements about the company's future expectations, plans and prospects are forward-looking statements. These forward-looking statements are based on management's current expectations. These statements are neither promises nor guarantees and involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from our expectations expressed or implied by the forward-looking statements
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
